A Phase Ib, First-In-Human, Dose Escalation and Expansion Study of XMT-1522, a Novel Antibody-Drug Conjugate (ADC) Directed Against HER2, in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2